



INTERIM MANAGEMENT DISCUSSION AND ANALYSIS
FOR THE THREE MONTHS AND NINE MONTHS ENDED SEPTEMBER 30, 2022.

(EXPRESSED IN CANADIAN DOLLARS)

FORWARD LOOKING STATEMENTS

This MD&A contains certain statements that may constitute “forward-looking statements”. Forward-looking statements include but are not limited to, statements regarding future anticipated business developments and the timing thereof, regulatory compliance, sufficiency of working capital, and business and financing plans. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made, and they involve several material risks and uncertainties. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: believe, expect, anticipate, intend, estimate, postulate, and similar expressions, or which by their nature refer to future events. The Company cautions investors that any forward-looking statements by the Company are not guarantees of future performance, and that actual results may differ materially from those in forward looking statements because of various factors, including, but not limited to, the Company’s ability to continue its projected growth, to raise the necessary capital or to be fully able to implement its business strategies.

The Company has based the forward-looking statements largely on the Company's current expectations, estimates, assumptions, and projections about future events and financial and other trends that the Company believes, as of the date of such statements, may affect its business, financial condition, and results of operations. Such expectations, estimates, assumptions, and projections, many of which are beyond the Company’s control, include, but are not limited to: management’s expectations regarding the future business, objectives and, operations of the Company; the Company’s anticipated cash needs and the need for additional financing; the Company’s ability to successfully complete future financings; the acceptance by the marketplace of new technologies and solutions; the Company’s expectations regarding its competitive position; the Company’s expectations regarding regulatory developments and the impact of the regulatory environment in which the Company operates; the Company’s ability to attract and retain qualified management personnel and key employees; and anticipated trends and challenges in the Company’s business and the markets in which it operates. Assumptions underlying the Company's working capital requirements are based on management's experience with other public companies.

Forward-looking statements regarding treatment by governmental authorities assumes no material change in regulations, policies, or the application of the same by such authorities. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made, and readers are advised to consider such forward-looking statements with the risks set forth.

The following Management’s Discussion and Analysis (“MD&A”) of Leveljump should be read in conjunction with the Company’s Unaudited Consolidated Financial Statements for the period ended September 30, 2022, together with notes thereto (the “Financial Statements”). The Company’s Unaudited Consolidated Financial Statements for the period ended September 30, 2022, have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”) and interpretations issued by the IFRS Interpretations Committee (“IFRIC”). All amounts herein are presented in Canadian dollars, unless otherwise noted. This Management’s Discussion and Analysis is dated November 29, 2022 and has been approved by the Board of Directors of the Company.

The Company's Audited Consolidated Financial Statements and its Annual Information Form are available on SEDAR at www.sedar.com

OVERALL PERFORMANCE

Summary of Business

Leveljump Healthcare Corp. was incorporated under the Canada Business Corporations Act on March 21, 2019 ("Jump" or the "Company"). The Company's registered head office is 304-85 Scarsdale Rd., Toronto, ON, Canada M3B 2R2. The Company's website is www.leveljumphealthcare.com.

The Company's principal business activity is providing radiology services both by providing direct patient images and by providing Teleradiology services. Teleradiology is the process of providing remote off site reading of radiology scans such as CT, MRI, US, and X-ray. Hospital staff scan their emergency room patients, then page the Company's radiologist on call, who can then remotely view, via secured server, the images and diagnose the patient and provide a report back to the hospital.

Results for Q3 2022

Total revenue for third quarter were strong at \$2,335,793.72 a 32% year over year increase from the third quarter of 2021. Revenue for the nine months ended was \$6,611,990, a year of year increase of over 34%.

Teleradiology revenues were \$1,813,642 which was an increase of 10.5% compared to the third quarter of 2021. The demand for CTS services is strong. Hospitals are trying to open access to more imaging overnight for their ER departments, which would increase the patient scan volume that CTS reads. Client hospitals have had some issues with staffing, and as the problem is resolved, we anticipate volume to increase further.

Revenues at the Company's IHF's totalled \$430,014 in the third quarter a slight increase over the second quarter of 2022. This is very encouraging as the summer months are generally the least busy months for diagnostic imaging.

During the quarter CTS announced a new client hospital the was signed for primarily overnight CT stat service. After the software set up and implementation, service commenced in mid September.

The Company did experience a tight labour pool, as is the experience with the broader healthcare market in Ontario. Efforts continue to recruit additional radiologists to ensure fluidity in coverage.

Industry Events and Trends

In Ontario, COVID 19, continues to have an affect on the healthcare system. As in many industries are experiencing labour shortages, healthcare has seen a shortage of nurses and doctors. The effects of the labour shortage on emergency room care and elective procedures is a strain on the system. Hospitals are trying to work with this new environment and in many cases attempt to reduce patient visits. This can help our IHF clinic business as hospitals are trying to reduce the amount of patient visits for non urgent care.

The Company believes that there is now a greater acceptance amongst the general population for telehealth services, than existed prior to the COVID-19 outbreak, and that ultimately this will enhance and improve our ability to acquire new contracts with hospitals. Key hospital decision makers such as department heads, radiologists, and hospital CEOs are now seeing the benefits of ensuring an uninterrupted flow of patient care via telehealth.

Management believes that hospitals and the healthcare industry in general will be looking for further ways to capitalize on the benefits of remote healthcare. This trend is expected to continue at a fast pace. Healthcare companies that can capitalize on it will be best served.

The healthcare system is now working through a backlog of imaging scans that were delayed due to the pandemic. This will continue for the foreseeable future as the healthcare system as to deal with both delayed imaging waitlists and new patients that require scans. For our IHF's, we are seeing high volume of bookings for imaging scans as people return to taking care of their health.

Outlook

Management believes that the Company's outlook for the fourth quarter of 2022 and first quarter of 2023 is strong based on several factors, including but not limited to, the increased demand for remote healthcare, and the general population's attitude shift to accepting the idea of telehealth services. With the Q1 2022 acquisition of our IHF clinics as well as potential organic growth from current operations, the Company expects to achieve increased revenues for the remainder of 2022.

The Company has acquired a fourth IHF license and plans to use it to establish a flagship x-ray and ultrasound center in north Toronto. The new center will be in the Yonge Sheppard Center and is expected to open in the first quarter of 2023. The company has recently secured two additional facilities with TD Canada Trust for the purchase of an existing IHF licence and for equipment and leasehold improvements for the IHF center. The Company is hopeful that its relationship with TD Canada Trust will grow into 2023 with the acquisition of more IHF centers.

The Company's focus for the remainder of 2022 will be to continue growing revenues via increased patient visits, increasing gross margins through cost reductions as well as identifying further acquisitions for 2023. Management continues to identify and target acquisitions that provide both stable revenues and positive EBITDA.

Financing and Share Issuances (See Notes 5, 11,12 and 13 in Financial Statements)

During the quarter ended September 30, 2022, the Company issued 1,000,000 shares of common stock in exchange for \$120,000 of accrued liabilities.

LIQUIDITY AND CAPITAL RESOURCES

As of September 30, 2022, the Company had cash and cash equivalents in the amount of \$637,589 (December 31, 2021 - \$767,611).

The Company's current assets as of September 30, 2022, excluding cash and cash equivalents were \$2,574,001 (December 31, 2021: \$1,936,773) which consisted of accounts receivable in the amount of \$934,115 (December 31, 2021: \$805,475), loans receivable in the amount of \$1,306,902 (December

2021: \$556,521), HST receivable for \$166,107 (December 2021: \$146,806) and prepaid expenses and deposits totalling \$166,876 (December 31, 2021: \$427,971).

Current liabilities as of September 30, 2022, were \$2,306,020 (December 31, 2021: \$1,952,184) which were comprised of accounts payables and accrued liabilities of \$1,794,852 (December 31, 2021: \$1,925,604), operating line of credit \$148,587 (December 2021: nil), current portion of lease liabilities \$98,629 (December 31, 2021: \$26,580) and current portion of long-term debt \$263,952 (December 31, 2021: nil).

The continuing operations of the Company are dependent upon its ability to raise adequate financing and to continue its operations in the future. For the quarter ended September 30, ~~2021~~ the Company had a net loss and comprehensive loss of \$737,217 and as of September 30, 2022, an accumulated deficit of \$15,348,680. These uncertainties may cast significant doubt upon the Company's ability to continue as a going concern.

Although the Company has been successful in borrowing funds or raising equity capital in the past, there can be no assurance that the Company will have sufficient financing to meet its future capital requirements, or that additional financing will be available on terms acceptable to the Company in the future. The Company has and may continue to have capital requirements more than its currently available resources.

Covid-19

In March 2020, the World Health Organization declared a global pandemic related to the virus known as COVID-19. The expected impacts on global commerce are anticipated to be far reaching. To date there have been significant wide-spread stock market declines and the movement of people and goods has become restricted. As the Company has no material operating income or cash flows, it will be reliant on additional financing to fund ongoing operations and future acquisitions. An extended disruption may affect the Company's ability to obtain additional financing. The impact on the economy and the Company is not yet determinable; however, the Company's financial position, results of operations and cash flows in the current period have been impacted as patient volume has decreased resulting in decreased revenues for the Company. The Company's financial position, results of operations and cash flows in future periods may be materially affected. There may be heightened risk of liquidity or going concern uncertainty.

Liquidity Risk

Liquidity risk is the risk that the Company cannot meet a demand for cash or fund its obligations as they become due. The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities as they become due. The Company is expanding and to meet its short and longer-term working capital requirements, the Company will attempt, if necessary, to secure further financing to ensure that those obligations are properly discharged. Operationally, the Company manages its liquidity by continuously monitoring forecasted and actual gross profit, expenses, and cash flows from operations. There have been no changes to this risk exposure from 2020.

The following tables illustrate the contractual maturities of financial liabilities for September 30, 2022, and December 31, 2021:

September 30, 2022	Payments Due by Period \$				
	Total	<1 year	1–3 years	3-5 years	5+ years
Accrued liabilities			-	-	-
	1,794,852	1,794,852			
Lease liabilities	298,250	98,629	199,621		
Long term debt	3,194,615	263,952	527,904	527,904	1,874,855
TOTAL	5,287,717	2,157,433	727,525	527,904	1,874,855

December 31, 2021	Payments Due by Period				
	Total	<1 year	1–3 years	3-5 years	5+ years
Accrued liabilities			-	-	-
	1,925,604	1,925,604			
Lease liabilities	26,580	26,580	-	-	-
Long term debt	-	-	-	-	-
TOTAL	1,952,184	1,952,184	-	-	-

CAPITAL RESOURCES

The Company defines capital as total shareholders' equity and long-term debt. The Company manages its capital structure, based on the funds available to the Company, to support the growth and development of its operations and bring new products to market and to ensure it continues as a going concern. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business. The Company will continue to assess new opportunities and seek to acquire an interest in growth situations if it feels there is sufficient economic potential and if it has adequate financial resources to do so.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There were no changes in the Company's approach to capital management during the quarter ended September 30, 2022 or the year ended December 31, 2021. The Company is not subject to externally imposed capital requirements other than those on its TD Long Term Debt which include priority rights against CTS, maintaining a debt to adjusted EBITDA ratio of 2.5 times as of December 31, 2022 and maintaining a debt service coverage ratio of not less than 115%.

OFF-BALANCE SHEET ARRANGEMENTS

The Company does not have any Off-Balance Sheet arrangements.

RELATED PARTY TRANSACTIONS AND BALANCES

Related parties include key management being the Company's executive officers, the Board of Directors, close family members and enterprises that are controlled by these individuals as well as certain persons

performing similar functions. The following related party transactions were conducted in the normal course of operations and were made on an arm's length basis:

Period Ended	September 30, 2022	December 31, 2021
Key management compensation	\$268,638	\$ 1,112,433
Share-based compensation	36,833	642,268
	\$ 305,471	\$ 1,754,701

THIRD QUARTER RESULTS

Quarter Ended	September 30, 2022	September 30, 2021
Total revenue	\$2,296,186	\$1,739,465
Gross margin	647,146	356,246
Operating Expenses	813,636	810,590
Net (loss) / income	(209,617)	(419,206)
Loss per share—basic and diluted	\$(0.002)	\$(0.009)

REVENUES

Teleradiology

For the three months ended September 30, 2022, the Company's teleradiology revenue increased by \$121,885 to \$1,813,642 compared to \$1,691,757 for the same period in 2021.

Diagnostic Imaging Services

For the three months ended September 30, 2022, the Company's Diagnostic Imaging Services revenue was \$430,014. There is no comparable data for the same period last year as this revenue was directly related to the IHF acquisition in February 2022.

Admin and Other

For the three months September 30, 2022, the Company's admin and other revenue was \$52,531 which increased by \$4,823 compared to admin revenue for the same period in 2021 of \$47,708.

TOTAL REVENUE

Total revenue for the three months September 30, 2022, was up \$556,721 to \$2,296,186 compared to \$1,739,465 for the three months ended September 30, 2021. The increase in total revenue is primarily a result of the revenues generated from the diagnostic imaging services.

COST OF SALES

Physician Fees

For the three months ended September 30, 2022, the Company's physician fees totaled \$1,431,687 higher by \$85,101 compared to physician fees of \$1,346,586 for the three months ended September 30, 2021. The increase in reading fees in the current three-month period is a result of the increased operations due to increased demand for the Company's services.

Technician Fees

For the three months ended September 30, 2022, the Company's technician fees totaled \$165,645. There is no comparable data for the same period last year as this was directly related to the IHF acquisition in February 2022.

Medical Imaging Software

PACS costs for the three months ended September 30, 2022, was \$44,072 compared to \$33,243 for the three-month period ended September 30, 2021. This increase was related to an increase in patient volume requiring diagnostic interpretation during the second quarter for 2022. Additionally, the increased costs are partially offset by amounts we can collect in administrative revenues.

Supplies

For the three months ended September 30, 2022, the Company's supplies costs totaled \$7,637 compared to \$3,390 for the three-month period ended September 30, 2021. The Company's supplies cost increased by \$4,247 for opening IHF centres.

TOTAL COST OF SALES

Total cost of sales during the third quarter in 2022 including physician fees, technical fees, medical imaging software, and supplies totalled \$1,649,041 compared to \$1,383,219. Higher cost of sales experienced during the third quarter in 2022, was primarily a result of costs associated with the IHF acquisition in addition to increased operations due to higher demand for the Company's services.

GROSS PROFIT

As a result of the above revenues net of cost of sales, the Company's gross margin increased by \$290,900 to \$647,146 for the three-month period ending September 30, 2022, versus gross margin of \$356,246 for the same three-month period in 2021.

EXPENSES

Stock Based Compensation

For the three months ended September 30, 2022, the Company recorded stock-based compensation of \$36,833 compared to \$104,732 for the same period in 2021. The decrease of \$67,899 is due to several options vesting in the first quarter of 2022 and not repeating in the third quarter.

Salaries and Wages

For the three months ended September 30, 2022, the Company recorded salaries and wages of \$415,271 compared to \$320,614 for the same three-month period ended September 30, 2021. The increase of \$94,657 in wages is for hiring new employees.

Advertising and Marketing

For the three months ended September 30, 2022, the Company recorded advertising and marketing expenses for \$4,616. Marketing and advertising expenses for the same period in 2021 was \$238,249. The significant decrease in advertising and marketing expenses occurred in the quarter were partly for contracts signed in 2021 for investor outreach and institutional outreach related to the Company's qualifying transaction and listing on the TSXV exchange that were not continued into 2022.

Professional Fees

For the three months ended September 30, 2022, the Company recorded professional fees of \$202,587 up considerably by \$133,527 compared to \$69,060 for the three months ended September 30, 2021. The increase in professional fees for the three months ended September 30, 2022, was primarily attributed to increased consulting fees in the second quarter due to revisions in management compensation contracts.

General and Administrative

General and administrative costs totaled \$60,417 up \$23,714 for the three months ended September 30, 2022, compared to general and administrative costs of \$36,703 for the same three-month period in 2021. The Company experienced an increase in general and administrative costs during the current period in fiscal 2022, because of additional expenses incurred by the IHF centres.

Insurance

Insurance expense for the three months ended September 30, 2022, decreased by (\$4,903) to \$25,335 when compared to \$30,238 for the same period in 2021.

Depreciation and Amortization

For the three months ended September 30, 2022, depreciation and amortization costs increased significantly by \$43,152 to \$51,335 compared to \$8,183 for the same period in 2021. This increase was due to additional amortization and depreciation on equipment and property related to the IHF centres.

Premises Rental

For the three months ended September 30, 2022, the Company's premises rental costs increased by \$14,432 to \$17,243 compared to \$2,811 for the same period in 2021. This increase reflects the rent due on the IHF centres.

TOTAL OPERATING EXPENSES

Total expenses for the three months ended September 30, 2022, were \$813,636, higher by \$3,046 when compared to total expenses of \$810,590 for the three months ended September 30, 2021.

OTHER INCOME

For the three months ended September 30, 2022, other income was \$188, whereas in 2021 for the same period it was nil. The other income is related to interest income and miscellaneous income.

OTHER EXPENSES

Finance Costs

For the three months ended September 30, 2022, the Company recorded finance costs of \$40,219 which increased significantly by \$37,724 versus finance costs of \$2,495 for the three-month period ended September 30, 2021. The increase in finance costs during the first quarter of 2022 was primarily related to interest on the TD Loan.

Other Miscellaneous Expenses

For the three months ended September 30, 2022, the Company recorded miscellaneous expenses at \$125 compared to \$(13,971) that was recorded for the same period in 2021. The miscellaneous expenses recorded in 2021 were related to an accounts payable write-off that were no longer due.

Foreign Exchange Loss

For the three months ended September 30, 2022, the foreign exchange loss was recorded at \$2,971 in the third quarter of 2022. In the third quarter of 2021 foreign exchange loss was recorded for (\$5,432).

TOTAL EXPENSES

Total expenses for the three months ended September 30, 2022, were \$856,952, increased by \$81,500 compared to \$775,452 for the three-month period ended September 30, 2021. The increase in total expenses for the three-month period ended September 30, 2022, was primarily related to salaries and wages, stock-based compensation and advertising and marketing expenses.

NET LOSS AND COMPREHENSIVE LOSS

As a result of the above factors, the net loss and comprehensive loss for the three months ended September 30, 2022, was (\$209,617) compared to a net income and comprehensive loss of (\$416,048) for the three months ended September 30, 2021.

NINE MONTH RESULTS

Period Ended	September 30, 2022	September 30, 2021
Total revenue	\$6,611,990	\$4,924,559
Gross margin	1,793,462	985,105
Operating Expenses	2,499,093	2,749,216
Net (loss) / income	(737,217)	(1,705,141)
Loss per share—basic and diluted	\$(0.01)	\$(0.039)

REVENUES

Teleradiology

For the nine months ended September 30, 2022, the Company's teleradiology revenue increased by \$549,806 to \$5,373,333 compared to \$4,823,527 in 2021.

Diagnostic Imaging Services

For the nine months ended September 30, 2022, the Company's Diagnostic Imaging Services revenue was \$1,100,151. There is no comparable data for the same period last year as this revenue was directly related to the IHF acquisition in February 2022.

Admin and Other

For the nine months September 30, 2022, the Company's admin and other revenue was \$138,506 which increased by \$37,474 compared to admin revenue for the same period in 2021 of 101,032.

TOTAL REVENUE

Total revenue for the nine months September 30, 2022, was up \$1,687,431 to \$6,611,990 compared to \$4,924,559 for the nine months ended September 30, 2021. The increase in total revenue is primarily a result of the increased teleradiology revenue and the revenue produced from the acquisition of the IFH centres.

COST OF SALES

Physician Fees

For the nine months ended September 30, 2022, the Company's physician fees totaled \$4,238,762 higher by \$394,800 compared to physician fees of \$3,843,962 for the nine months ended September 30, 2021. The increase in reading fees in the current nine-month period is a result of the increased operations due to increased demand for the Company's services.

Technician Fees

For the nine months ended September 30, 2022, the Company's technician fees totaled \$410,719. There is no comparable data for the same period last year as this was directly related to the IHF acquisition in February 2022.

Medical Imaging Software

PACS costs for the nine months ended September 30, 2022, was \$148,790 compared to \$85,025 for the nine-month period ended September 30, 2021. This increase was related to an increase in patient volume requiring diagnostic interpretation during the second quarter for 2022. Additionally, the increased costs are partially offset by amounts we can collect in administrative revenues.

Supplies

For the nine months ended September 30, 2022, was \$20,256 increased by \$9,789 compared to \$10,467 for the same period ended last year.

TOTAL COST OF SALES

Total cost of sales during the first half of 2022 including physician fees, technician fees, medical imaging software, and supplies expenses were \$4,818,527 compared to \$3,939,454. Higher cost of sales experienced during the first half of 2022 was primarily a result of costs associated with the IHF acquisition in addition to increased operations due to higher demand for the Company's services.

GROSS PROFIT

As a result of the above revenues net of cost of sales, the Company's gross margin increased by \$808,357 to \$1,793,462 for the nine-month period ending September 30, 2022, versus gross margin of \$985,105 for the same nine-month period in 2021.

EXPENSES

Stock Based Compensation

For the six months ended September 30, 2022, the Company recorded stock-based compensation of \$256,499 compared to \$707,753 for the same period in 2021. The decrease of (\$451,254) is due to a fewer number of options granted in 2022 as compared to the year prior.

Salaries and Wages

For the nine months ended September 30, 2022, the Company recorded salaries and wages of \$1,130,570 compared to \$923,551 for the same three-month period ended September 30, 2021. The increase in salaries recorded in the third quarter of fiscal 2022 was a result of hiring new employees in the IHF centers.

Advertising and Marketing

For the nine months ended September 30, 2022, the Company recorded advertising and marketing expenses for \$21,004. Marketing and advertising expenses for the same period in 2021 was \$620,486. The significant decrease in advertising and marketing expenses occurred in the first half of the quarter were partly for contracts signed in 2021 for investor outreach and institutional outreach related to the Company's qualifying transaction and listing on the TSXV exchange that did not continue into 2022.

Professional Fees

For the nine months ended September 30, 2022, the Company recorded professional fees of \$658,601 up considerably by \$365,519 compared to \$293,082 for the nine months ended September 30, 2021. The increase in professional fees for the nine months ended September 30, 2022, was primarily attributed to increased consulting fees in the second quarter due to revisions in management compensation contracts.

General and Administrative

General and administrative costs totaled \$174,178 up \$76,670 for the nine months ended September 30, 2022, compared to general and administrative costs of \$97,508 for the same nine-month period in 2021. The Company experienced an increase in general and administrative costs during the current period in fiscal 2022, because of additional expenses incurred by the IHF centres.

Insurance

Insurance expense for the nine months ended September 30, 2022, increased by \$1,565 to \$72,291 when compared to \$73,856 for the same period in 2021.

Depreciation and Amortization

For the nine months ended September 30, 2022, depreciation and amortization costs increased significantly by \$120,820 to \$145,368 compared to \$24,548 for the same period in 2021. This increase was due to additional amortization and depreciation on equipment and property related to the IHF centres.

Premises Rental

For the nine months ended September 30, 2022, the Company's premises rental costs increased by \$32,149 to \$40,581 compared to \$8,432 for the same period in 2021. This increase reflects the rent due on the IHF centres.

TOTAL OPERATING EXPENSES

Total expenses for the nine months ended September 30, 2022, were \$2,499,093, lower by (\$250,123) when compared to total expenses of \$2,749,216 for the nine months ended September 30, 2021. The primary factors relating to the decrease in total expenses during the third quarter of 2022 were due the decrease in advertising and marketing by (\$599,482), insurance decrease (\$1,565) and stock-based compensation (\$451,254).

OTHER INCOME

For the nine months ended September 30, 2022, other income was \$102,958, whereas in 2021 for the same period it was \$20,000. The increase in other income for the first half of 2022 is related to recapture of allowance for payroll taxes.

OTHER EXPENSES

Finance Costs

For the nine months ended September 30, 2022, the Company recorded finance costs of \$100,358 which increased significantly by \$91,616 versus finance costs of \$8,742 for the nine-month period ended September 30, 2021. The increase in finance costs during the first half of 2022 was primarily related to interest on the TD Loan.

Broker Commissions

For the nine months ended September 30, 2022, the Company recorded broker commission costs of \$20,201. There was no comparable amount for the same period in 2021 as this relates to broker commission costs from private placement financing.

Reconciliation Discrepancies

For the nine months ended September 30, 2022, the Company reconciliation discrepancies of \$7,808. There was no comparable amount for the same period in 2021. These costs were directly related to reconciliation discrepancies which the company faced as a direct result of migrating between two accounting systems.

Other Miscellaneous Expenses

For the nine months ended September 30, 2022 the Company recorded (\$1,419) for miscellaneous expenses, compared to (\$46,231) that was recorded for the same period in 2021. The miscellaneous expenses recorded in 2021 were related to an accounts payable write-off that were no longer due.

Foreign Exchange Loss

Foreign exchange loss of \$2,971 was recorded in the third quarter of 2022 compared to (\$1,481) a decrease in the same period in 2021.

NET LOSS AND COMPREHENSIVE LOSS

As a result of the above factors, the net loss and comprehensive loss for the nine months ended September 30, 2022, was (\$737,217) compared to a net loss and comprehensive loss of (\$1,705,141) for the nine months ended September 30, 2021, an increase of \$967,924.

LOSS PER SHARE – BASIC AND DILUTED

The loss per share-basic and diluted for the nine months ended September 30, 2022, was \$0.01 versus the loss per share-basic and diluted of \$0.039 for the comparable period in 2021.

PROPOSED TRANSACTIONS

The Company does not have any proposed transactions.

CHANGES IN ACCOUNTING POLICIES

The Company adopted an equipment depreciation schedule for its newly acquired medical equipment and leasehold improvements which includes a straight-line method and a useful life of 10 years. There were no other accounting policy changes in the first half of the year, and none are planned for the remainder of 2022.

FINANCIAL INSTRUMENTS AND OTHER INSTRUMENTS

On February 1, 2022, the Company's subsidiary CTS borrowed \$3,200,000 from TD Canada Trust. The initial term of the loan is 5 years with an initial 2-year interest rate of 4.02%. The loan is amortized over 10 years. Payments of principal and interest on the loan are due monthly. There is an additional annual payment of principal on the balance of the loan based on 25% of EBITDA of the Company's CTS subsidiary.

Credit risk

Credit risk is the risk of loss associated with a counter-party's inability to fulfill its payment obligations. The Company's cash and accounts receivable are exposed to credit risk. Jump's cash is held with a major Canadian-based financial institution and as such management believes that the associated credit risk is remote.

Account receivables represents revenue earned from services rendered to hospitals. The Company has adopted a credit policy under which each new customer is analyzed individually for creditworthiness before the Company's standard payment terms and conditions are offered.

The Company's trade receivables are concentrated among customers in the healthcare industry, which may be affected by adverse government policy impacting that industry. As of September 30, 2022, three customers accounted for greater than 63% of the Company's trade receivable balance.

There have been no changes to this risk exposure from 2021.

The Company's maximum exposure to credit risk as of September 30, 2022 and December 31, 2021, was as follows:

	June 30, 2022	December 31, 2021
Cash and Cash Equivalents	\$ 637,589	\$ 756,260
Accounts Receivable	934,115	727,983
Loans Receivable	1,306,902	556,521
Prepaid Expenses and Deposits	166,876	427,971
Total	\$3,045,482	\$ 2,468,735

SHARE CAPITAL AND RESERVES

Authorized Share Capital

As at the date of filing this report the Company had 85,043,229 common shares outstanding. There are no other approved classes of shares for the Company.

Stock Options

As at the date of filing this report the Company had 9,334,890 options issued and outstanding, of which 7,185,890 are vested and exercisable into shares of common stock. (see Interim Financial Statements Note 14)

Warrants

As at the date of filing this report the Company had 40,860,261 common share purchase warrants issued and outstanding. (see Interim Financial Statements Note 15)

Broker Options

As at the date of filing this report the Company had 696,040 broker options issued and outstanding, each convertible into a unit consisting of 1 common share and 1 common share purchase warrant. (see Interim Financial Statements Note 16)